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ABSTRACT
Tumor-initiating cells (TICs) in squamous cell carcinoma of the head and neck
(SCCHN) are best characterized by their surface expression of CD44. Although there
is great interest in identifying strategies to target this population, no marker of these
cells has been found to be functionally active. Here, we examined the expression of
the purported marker of normal human oral epithelial stem cells, CD271. We show
that CD271 expression is restricted to a subset of the CD44+ cells. Using xenograft
assays, we show that the CD44+CD271+ subpopulation contains the most tumorigenic
cells. Loss of CD271 function results in a block in the G2-M phase of the cell cycle and
a profound negative impact on the capacity of these cells to initiate tumor formation
in vivo. Incubation with recombinant NGF results in enhanced phosphorylation of Erk,
providing additional evidence that CD271 is functionally active. Finally, incubation
of SCCHN cells with antibody to CD271 results in decreased Erk phosphorylation
and decreased tumor formation in vivo. Thus, our data are the first to demonstrate
that CD271 more specifically identifies the TIC subpopulation within the CD44+
compartment in SCCHN and that this receptor is a functionally active and targetable
molecule.

INTRODUCTION

neoplasms of the upper aerodigestive tract. While there
have been some modest improvements in the treatment
of advanced cases, recurrence rates are still as high as 3050% for tobacco-related SCCHN, and the therapy alone

Squamous cell carcinoma of the head and neck
(SCCHN) is one of the most common malignant
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Table 1: Expression of CD271 in human primary SCCHN samples measured by immunohistochemistry

Oropharyngeal (%)

Non-Oropharyngeal (%)

Total (%)

CD271+

154 (76)

47 (58)

201(71)

CD271-

48 (24)

34 (42)

82 (29)

– which includes a combination of surgery, chemotherapy,
and radiation – often results in significant morbidity and
long-term functional toxicity, negatively affecting critical
functions such as speech and swallowing.
Tumor-initiating cells (TICs) in solid tumors
represent a subpopulation of cells that have the ability
to propagate tumor formation in vivo and have been
associated with recurrence of disease and poor clinical
outcomes due to their metastatic capacity and resistance
to conventional chemotherapy and radiation. In SCCHN,
the hyaluronic acid receptor CD44 has reproducibly been
shown to be a marker that can distinguish these cells from
non-TICs [1]. Specifically, the CD44+ population has been
shown to contain the TIC subpopulation, since purified
CD44+ cells from heterogenous primary tumors are able to
give rise to tumors much more readily in xenograft model
systems compared to CD44- cells, and these xenograft
tumors subsequently reproduce the original tumor
heterogeneity observed in the primary tumor. Importantly,
the CD44+ population has also been discovered to have a
greater capacity to handle oxidative stress and, as such,
is more radioresistant [2]. This population has also been
shown to have a significantly greater ability to metastasize
to regional lymph nodes in animal models [3], and patients
whose tumors have greater percentages of CD44+ cells
have a significantly poorer clinical outcome [4]. Thus,
there has been a strong growing interest in identifying
strategies to target these cells. However, the discovery of
targetable functional molecules identifying the TICs in
SCCHN has remained elusive.
In normal human oral epithelium, a subpopulation
of cells with stem cell – like properties has been shown to
express a cell surface molecule, designated as the CD271
antigen [5, 6]. This molecule, also known as the low
affinity nerve growth factor (NGF) receptor or p75NTR, is a
neurotrophin receptor and a member of the tumor necrosis
factor receptor superfamily. In the nervous system, it
has critical functions in cell survival [7], differentiation
[8], and migration [9] of neuronal cells . Recently, this
molecule has been identified as a marker of TICs in human
melanoma [10, 11], esophageal carcinoma [12, 13], and
hypopharyngeal carcinoma [14]. In addition to being
expressed in discrete cells within the basal layer of normal
oral epithelium, CD271 is also expressed in oral dysplasia
www.impactjournals.com/oncotarget

and oral squamous cell carcinoma [15]. Importantly, the
increased expression of CD271 has been associated with
a poorer clinical outcome in esophageal cancer [16, 17],
hypopharyngeal cancer [14], and oral squamous cell
carcinoma [15, 18].
In this study, we show that cells expressing CD271
in human and mouse SCCHN comprise a distinct subset of
the CD44+ cells and that these CD44+CD271+ cells possess
the greatest tumor-initiating capacity in this malignancy.
Further, our data demonstrate that this receptor is
functional in SCCHN and that inhibition of CD271 has
profound negative effects on SCCHN tumor-initiating
capacity, providing evidence for the first functional and
targetable molecule specific to TICs in this malignancy.

RESULTS
CD271 is expressed in the majority of head and
neck SCC
We assessed the prevalence of CD271 expression in
head and neck SCC by immunohistochemical staining of a
tissue microarray (TMA) containing 283 specimens from
primary tumors (Table 1). Overall, 71% of the tumors
showed strong positive CD271 staining (representative
staining shown in Supplemental Figure 1). No correlation
was observed with a particular anatomic site or with
clinical parameters, such as TNM staging and outcome.
However, these specimens represent a heterogeneous
collection of mucosal tumors, including those from the
oral cavity, oropharynx, hypopharynx, and larynx. There
were a higher percentage of CD271+ tumors among the
oropharyngeal SCC group of tumors, the majority of
which were human papilloma virus positive, but there was
no statistically significant difference in CD271 expression
by HPV DNA or p16 status (data not shown).
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CD271 is expressed on a discrete subset of
SCCHN cells that have the capacity to initiate
tumors

by flow cytometry. Importantly, the CD271+ cells
comprised a subpopulation among the CD44+ cells in
these primary tumors, but there was no appreciable CD44CD271+ subpopulation (Figure 1A). A distinct CD271+
subpopulation of cells was also observed in cell lines
derived from both mouse and human oral squamous cell
carcinoma (Figures 1B and 1C).
Because CD271 has been associated with normal
and cancer stem cell phenotypes, we assessed whether
CD271+ cells had a greater capacity for tumor initiation
in vivo. Specifically, we were interested in determining
whether the CD271+ cells possessed the primary tumor
initiating capacity among the CD44+ population and if
the CD44+CD271+ cells represented the more specific
TIC population in SCCHN. To test this, we sorted the
CD44+CD271+ cells, CD44+CD271- cells, and CD44CD271- cells from primary human oral SCC specimens
(Supplemental Figure 2) and implanted them into the
flanks of immunodeficient Rag-/-γc-/- mice in a limiting
dilution fashion. Overall, the CD44+ cells had greater

The expression pattern of CD271 in SCCHN
was interesting in that there was discrete expression of
this receptor on a distinct subpopulation of cells in oral
SCC. Among well-differentiated oral SCC tumors, the
expression of CD271 was in the “basal” aspect of the
malignant epithelium, which maintained polarity (Figure
1A). This basal expression is consistent with what has
been described in normal human oral epithelium among
cells possessing stem cell – like properties [5]. In tumors
that were more poorly differentiated, there was more
disorganized expression of CD271, but the subpopulation
that was positive for the receptor was still distinct and
separate from the CD271- cells. This discrete expression
pattern was also observed in dissociated primary tumor
cells that were stained for CD44 and CD271 and analyzed

Figure 1: CD271 is heterogeneously expressed in SCCHN and marks the more tumorigenic population of cells. (A)

Human primary SCCHN samples were stained with a monoclonal antibody against CD271 and assessed by immunohistochemistry and
flow cytometry. The FACS plot is gated on the DAPI-lineage- population and co-stained for CD44 and CD271. (B) Two murine cell lines
derived from oral tumors arising from DMBA-treated oral cavity mucosa were stained with a monoclonal antibody specific for murine
CD271 and assessed by FACS. (C) Human cell lines derived from head and neck SCC were assessed for CD271 expression by FACS after
staining with a monoclonal antibody to CD271.
www.impactjournals.com/oncotarget
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Table 2: Xenograft tumor formation with sorted population of human and mouse SCCHN cells
Human Primary Head and Neck SCC Tumor #1
Cells Injected
CD44-CD271CD44+CD271CD44+CD271+

50,000
2 of 2

5,000
0 of 2
5 of 6

500
0 of 6
0 of 6
3 of 5

10,000
5 of 6
8 of 8
8 of 8

1,000
4 of 6
7 of 8
8 of 8

Human Primary Head and Neck SCC Tumor #2
Cells Injected
CD44-CD271CD44+CD271CD44+CD271+

100,000
2 of 2
2 of 2
2 of 2

100
4 of 8
8 of 8

Mouse Oral SCC Cell Line: MOC2
Cells Injected
CD271CD271+

10,000
0 of 5
3 of 5

Mouse Oral SCC Cell Line: MOC10
Cells Injected
CD271CD271+

10,000
0 of 5
3 of 5

capacity to form xenograft tumors compared to the CD44cells, but when low numbers of cells were injected, it was
clear that the CD44+CD271+ cells had the greatest capacity
to form tumors among these three populations (Table
2); The tumors that formed in mice implanted with the
CD44+CD271+ cells recapitulated the heterogeneity seen
in the parental tumor (Supplemental Figure 3). Similarly,
when mouse oral SCC cell lines (which were uniformly
CD44+, data not shown) were sorted into CD271+ and
CD271- populations, the CD271+ cells had significantly
greater capacity to form tumors in vivo compared to
the CD271- cells(Table 2). Thus, in SCCHN, the TIC
population is marked by the expression of both CD44 and
CD271.

the highest percentages of CD271+ cells in mice resulted in
the most robust in vivo tumor growth (Figure 2A). Because
CD271 has been shown in other systems to modulate
cell proliferation and survival [19-22], we investigated
whether or not CD271 loss-of-function would have an
effect on cell proliferation and tumor initiation. To do
this, we expressed validated shRNA molecules targeting
CD271 in SCCHN cells by lentiviral transduction. The
knockdown of CD271 significantly affected cell growth
in vitro (Figure 2C). In an MTT assay, the CD271hi cell
lines (UPCI:SCC-103 and PCI-13), that were transduced
with the CD271 shRNA, grew significantly more slowly
compared to controls. This growth was rescued by cotransducing the coding sequence for CD271, which lacked
the 3’-UTR targeted by the shRNA (Figure 2D); thus, the
reduced growth conferred by the shRNA was specific for
CD271. Mechanistically, this appears to be due to a partial
cell cycle block in the G2-M transition and not apoptosis
(Figure 2E and Supplemental Figure 4). Thus, for cells
expressing CD271, the receptor appears to be required for
cell cycle progression.
To assess if CD271 expression also affected tumor
initiation and growth in vivo, the PCI-13 oral SCC cell
line, which was uniformly CD271+, was transduced with
either a lentivirus that co-expressed the CD271 shRNA

Knockdown of CD271 in SCCHN inhibits cell
proliferation and tumor formation
As with primary head and neck SCC, the expression
of CD271 in human SCCHN cell lines was heterogeneous
(Figure 1C). Among the four SCCHN cell lines that we
examined, there were varied percentages of CD271+
cells. Although these cell lines had similar growth
characteristics in vitro, implantation of the two lines with
www.impactjournals.com/oncotarget
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and mCherry or a lentivirus expressing GFP. The two sets
of transduced cells were mixed at a 1:1 ratio and then
injected into immunodeficient Rag-/-γc-/- mice (Figure 3).
The tumors that formed were subsequently dissociated
into single cells and analyzed by FACS, after excluding
any infiltrating mouse cells (stained for mouse MHC class
I). The tumors were found to be highly enriched for GFP+
cells even though the cells that were injected were initially
50% mCherry+ and 50% GFP+ (Figure 3B). This was the
case only when the CD271 shRNA was co-expressed in the

mCherry construct. If a an mCherry control lentivirus was
used, the resulting tumor remained approximately 50%
mCherry+ and 50% GFP+. Thus, knockdown of CD271
resulted in cells that were significantly less tumorigenic
compared to control cells in the same microenvironment,
indicating that CD271 is a functional receptor expressed
on the tumor-initiating population in SCCHN.

Figure 2: CD271 loss-of-function results in decreased cell cycle progression in SCCHN. (A) Four cell lines derived from

human SCCHN were assessed for in vitro growth kinetics by MTT assay and for in vivo tumor formation and growth by implantation
into the flanks of Rag-/-γc-/- mice. (B) Knockdown of CD271 in human SCCHN cell lines by shRNA lentiviral constructs was assessed by
FACS. (C) Effects of CD271 knockdown by shRNA expression on cell proliferation was assessed by MTT assay. In the cell lines with
high expression of CD271 (UPCI:SCC-103 and PCI-13), there was a decrease in cell viability at the end of the MTT assay. Two different
shRNAs were assessed: “sh3” = CD271 shRNA3. “sh5” = CD271 shRNA5. (D) The effects of the CD271 knockdown was reversed by
co-expression of the CD271 coding sequence that lacked the 3’-UTR, which was targeted by the shRNA. In the FACS plots, the rescued
expression of CD271 is demonstrated in the plot on the right. The bar graph represents the fold change in cell viability at the end of an MTT
assay (relative to day 0). “c” = empty vector control or scramble RNA control. “p75”= CD271 coding sequence lacking the 3’-UTR. “sh3”
= CD271 shRNA3. “sh5” = CD271 shRNA5 *p<0.01, **p<0.005. (E) PCI-13 cells were transduced with lentivirus expressing CD271
shRNA3, CD271 shRNA5, or a scrambled control RNA. Percentages of cells in the various phases of the cell cycle were assessed by FACS
after staining with BrdU and PI; these percentages are quantified in the bar graph. *p<0.01.
www.impactjournals.com/oncotarget
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Targeting CD271 with a monoclonal antibody
inhibits in vivo tumor formation by SCCHN cells
and inhibits phosphorylation of Erk

vitro and assessed activation of the MAP kinase pathway
(Figure 4B). NGF treatment resulted in an increase in
Erk phosphorylation detected by Western immunoblot.
Furthermore, preincubation with the monoclonal antibody
to CD271 abrogated this increase in Erk phosphorylation.
There was, however, no apparent effect on the PI3 kinase
pathway since p-Akt was not affected (data not shown).
Our data indicate that CD271/NGFR is functionally active
in SCCHN and that targeting CD271 with a monoclonal
antibody is a potential therapeutic strategy in this cancer.

The inhibition of in vivo tumor formation with
CD271 loss-of-function suggested that this molecule
might be a viable therapeutic target in SCCHN. To
address this hypothesis, we targeted the receptor with
a monoclonal antibody specific for NGFR. Incubation
of PCI-13 SCCHN cells with the antibody resulted in a
significant reduction in cell proliferation in vitro compared
to cells treated with isotype control IgG (Figure 4A).
Furthermore, treatment of the cells with the anti-NGFR
antibody resulted in significant reduction in tumor growth
in vivo compared to isotype control – treated cells.
CD271/NGFR activation has been previously
shown to work through downstream activation of both
the MAP kinase and PI3 kinase pathways [23]. To
determine the functional role of CD271 in SCCHN, we
treated PCI-13 cells with recombinant human NGF in

DISCUSSION
In this study, we extend the current understanding
and characterization of TICs in SCCHN. We demonstrate
that among the CD44+ cells in SCCHN, the CD44+CD271+
cells are the more specific TIC population. In addition,
we show that CD271 is a functional cell surface molecule
that responds to NGF ligand activation and signals through
the MAP kinase pathway. CD271 loss-of-function in

Figure 3: CD271 loss-of-function results in decreased tumor initiation in vivo. (A) Schematic of in vivo competition assay.

PCI-13 cells were transduced with either a lentivirus co-expressing shRNA targeting CD271 and mCherry or a lentivirus expressing
Zsgreen. Cells were mixed 1:1 and injected into the flanks of Rag-/-γc-/- mice. Cell composition in tumors arising in these mice was assessed
by FACS analysis of cells from dissociated tumors. (B) FACS analysis of input cells at time of implantation and cells from dissociated
tumors at the termination of the experiment. The bar graphs depict the percentages of mCherry and Zsgreen expressing tumor cells from
each cohort of recipient mice.
www.impactjournals.com/oncotarget
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these tumor cells results in a significant decrease in their
capacity for tumor initiation, and targeting CD271 with
a monoclonal antibody results in the inhibition of tumor
growth in vivo. Thus, our data provide rationale for the
targeting of CD271 as a therapeutic strategy.
Our data are consistent with the idea that the TIC
population originates from a deregulated normal stem cell
population. In normal human oral epithelium, a CD271
expressing subpopulation of cells in the basal layer has
been shown to have a stem cell – like phenotype [5].
These CD271+ cells have a greater proliferative capacity,
form colonies more robustly in vitro, and form layers of
cells expressing more differentiated markers, resembling
stratified epithelium when cultured on amniotic
membranes. Furthermore, the incubation of the CD271+,
but not CD271-, cells, isolated from normal human oral
epithelium, with NGF resulted in enhanced proliferation.
Because CD44 is expressed in the basal half of the oral
epithelium, CD271+ cells comprise a subset of the CD44+
cells in normal epithelium, similar to what we have found
in SCCHN. Thus, it is likely that the CD44+CD271+ cells
in SCCHN retain many of the stem cell – like properties
of this subpopulation in normal epithelium.
Interestingly, not all of the SCCHN tumors express

CD271. This heterogeneity between SCCHN tumors
indicates that in some tumors, the TIC population is
marked by CD271, but in other tumors, the TIC population
may be completely different phenotypically. This may
reflect a different cell of origin for the TIC population
in CD271+ tumors compared to CD271- tumors. It is
possible that inciting mutation(s) can occur at different
stages of epithelial differentiation and that, consequently,
the markers identifying the resulting TIC subpopulation in
SCCHN may be different.
Interest in specific strategies to target the TIC
population has been gaining traction in recent years with
increasing evidence that these cells are more resistant to
conventional chemotherapy and radiation therapy in a
number of cancer types [24]. In SCCHN, there is evidence
that the CD44+ population is able to handle oxidative stress
better than the CD44- population and that the CD44+ cells
are enriched after SCCHN xenografts are treated in vivo
with radiation [2]. Our data would suggest that in CD271+
SCCHN tumors, the CD44+CD271+ cells would comprise
the population most resistant to radiation-induced
oxidative stress. Supporting this hypothesis is evidence
that neurotrophins can increase tolerance of PC12 cells
to reactive oxygen species in a CD271-dependent manner

Figure 4: Targeting of CD271 with monoclonal antibody inhibits tumor formation and NGF-induced Erk
phosphorylation. (A) PCI-13 cells were incubated with either azide-free monoclonal antibody specific for CD271 or isotype control IgG

for 30 min, washed, and then assessed for cell proliferation in vitro and tumor growth in vivo. The graph on the left shows MTT cell viability
results over 8 days, expressed as fold-change from the day 0 baseline. The graph on the right shows tumor growth from cells injected
subcutaneously into the flanks of Rag-/-γc-/- mice. Each cohort consists of 4 mice. Experiments were performed at least two times. (B) PCI13 cells (grown in serum-free medium for 24 hrs) were incubated in vitro with monoclonal antibody to CD271 or isotype control IgG for 30
min and then with or without recombinant human NGF for 1 hr. Cell lysates were subjected to gel electrophoresis, and Western immunoblot
analysis was performed with antibody specific for phosphorylated-Erk (p-Erk1/2), total Erk, and actin. All experiments performed two or
more times.
www.impactjournals.com/oncotarget
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[25]. Indeed, in esophageal squamous cell carcinoma,
the CD271+ cells have been demonstrated to be more
resistant to cisplatin, which like radiation, exerts its
cytotoxic activity in part through oxidative stress [12, 26].
Since both cisplatin and radiation are mainstay treatment
modalities in SCCHN, future work will be focused on
assessing the ability of CD271 inhibition to enhance
chemoradiation sensitivity of these CD44+CD271+ TICs.
Multiple studies have observed a correlation
between the percentages of TICs, or cancer stem cells,
within primary tumors and clinical outcome. In SCCHN,
the percent of CD44+ cells has been correlated with
regional metastatic recurrence [4]. Our data, together with
what has been observed in esophageal carcinoma [16,
17], hypopharyngeal carcinoma [14], and oral carcinoma
[15, 18], would suggest that the percent of CD44+CD271+
cells might also provide prognostic information. One of
the significant adverse features seen with some SCCHN
tumors is perineural invasion (PNI), which has been
associated with local recurrence and metastases [27].
Since Schwann cells around neurons and epithelium
rich in neurons express NGF [28, 29], it is possible that
expression of CD271 may predispose tumor cells to PNI.
Indeed, in malignant melanoma, expression of CD271
has been associated with PNI [30], and in oral cancer and
pancreatic cancer [31-33], the expression of NGF has also
been associated with PNI. In our set of SCCHN samples
examined on the TMA, we did not observe an association
between CD271 expression and PNI as recorded from
pathology reports (data not shown). However, our set
consisted of a heterogeneous group of head and neck
tumor sites, and further examination of this is needed.
Our data that CD271 signals through the MAP
kinase pathway in SCCHN is the first description of
an actively signaling receptor that marks TICs in this
malignancy. Although CD271 has also been described
to signal through the PI3 kinase pathway [34], we did
not observe any alterations in Akt phosphorylation with
activation or inhibition of CD271 (data not shown). The
feasibility of targeting CD271 to affect the viability of
CD44+CD271+ cells in SCCHN and their capacity for
tumor initiation is demonstrated by our study. In addition
to targeting these cells with monoclonal antibody therapy
in vivo, it will be interesting to see if MEK inhibition in
these cells can also specifically reduce their viability and/
or sensitize them to cisplatin or radiation.

as previously described [35, 36]. These specimens
represented a heterogeneous collection of oropharyngeal
(tonsil and base of tongue) and non-oropharyngeal
(including sites from the oral cavity, hypopharynx, and
larynx), retrospectively identified in pathology hospital
files. All cases got two punches from areas of tumor
that were designated by the study pathologist (JSL) with
a dotting pen on the original H&E slides. According to
the amount of available biopsied or resected tumor tissue,
duplicate two millimeter (or if inadequate tumor tissue
present, 0.6 millimeter) punches were taken from each
case. Since most of the cases (75%) were treated with
primary surgery, the majority of cases on the array had
the larger (two millimeter) punches. For the oropharyngeal
SCC patients, DNA in situ hybridization for high risk
human papillomavirus and p16 immunohistochemistry
had been previously performed on whole tissue sections,
as previously described [37]. CD271 expression was
assessed by the study pathologist (JSL) visually and
considered simply as a binary result: positive = any tumor
cell staining and negative = no tumor cell staining.

Mice and Cell Lines
Female Rag2-/-γc-/- mice (6-12 weeks old) in a Balb/c
background were a kind gift from Dr. Irving L. Weissman
(Stanford) and were bred in our animal facility under
specific pathogen-free conditions. All animal procedures
were conducted under institutional guidelines that comply
with national laws and policies. The human HNSCC cell
line UM-SCC-6 was obtained from Dr. Thomas Carey
at the University of Michigan. The oral SCC-4 cell line
was obtained from ATCC. The oral oUPCI:SCC103
and PCI-13 cell lines were kind gifts from Dr. Suzanne
Gollin Theresa Whiteside and Dr. Jennifer Grandis at
the University of Pittsburgh. Cells were maintained in
complete DMEM:F12 medium (DMEM:F12 1:1 with
Glutamax [Gibco, Invitrogen, CA] containing: 10% heatinactivated FBS [Cellgro, MA], 100 IU/ml penicillin
and 100 μg/ml streptomycin [Gibco, Invitrogen, CA]).
The HEK293T cell line was obtained from ATCC and
maintained in complete DMEM medium. The MOC2 and
MOC10 murine oral SCC cell lines were developed by Dr.
Ravindra Uppaluri at Washington University [38].

Antibodies

METHODS
Formalin Fixed
Microarray

Paraffin-Embedded

Monoclonal antibodies to CD31 (WM-59), CD45
(30-F11), CD44 (G44-26), CD271 (C40-1457) for flow
cytometry and sorting were obtained from BD Biosciences.
Antibody to mouse CD271 (mu p75) was obtained from
Advanced Targeting Systems. Antibody to fibroblasts
(TE-7) was obtained from Millipore. Anti-mouse H-2Kd
antibody (SF1-1.1) was obtained from BD Biosciences.
Antibody to CD271 (NGFR5) for immunohistochemistry

Tissue

The tissue microarray (TMA) containing 283
specimens from patient primary tumors was constructed
www.impactjournals.com/oncotarget
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and blocking experiments was obtained from Abcam and
Thermo Scientific. Antibodies to phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) (E10) and total Erk were
obtained from Cell Signaling Technologies. Antibody to
actin was obtained from Thermo Scientific.

shp75NTR1(5’CCGGGCAC TGTAGT AAATGGCA
ATTCTCG AGAATT GCCATTTACTACAGT GCT
TTTTG3’),shp75NTR2(5’CCGGCCTCCAGAACA
AGACCTCATACTCGAGTATGAGGT
CTTGTTCT
GGAGGTTTTTG3’),shp75NTR3(5’CCGGCCAGCC
TAAGATGAAGAGGATCTCGAGA TCCTCTTCATC
TTAGGCTGGTTTTTG3’),shp75NTR4(5’CCGGCCT
TCA CTTCTGACCACACTTCTCGAGA AGTGTGGT
CAGAAGTGAAGGTTTTTG3’),shp75NTR5(5’CCGG
GCGGCA AGAAGGAATTGACTTCTCGAGAAGTC
AATTCCTTCTTGCCGCTTTTTG3’).
The lentiviral constructs pHIV-Zsgreen and pHIVmCherry were kind gifts from Dr. Michael Clarke
(Stanford). A cDNA from the ATG codon to the stop
codon of human p75NTR was PCR cloned (forward primer:
5’CATTAGCGGCCGC ACCATGGGGGCAGGTGCC-3’;
reverse
primer:5’CTGGTCTAGATCACACC
GGGGATGTGGCAGTG-3’) and NotI/XbaI inserted into
the pHIV-Zsgreen vector.

Tumor Digestion and In Vivo Xenograft Assays
Patient tumor samples were obtained fresh from
the operating room after a consenting process that was
approved by the Institutional Review Board. Tumor
cell dissociation was performed, as follows. Briefly,
tumors were minced and then digested with collagenasehyaluronidase (Stem Cell Technologies) for 16 hrs at 37
deg C. Following this, the cells were treated for 3 min with
trypsin-EDTA, washed, treated with dispase and DNase I
(Stem Cell Technologies) for 1 min, washed, filtered, and
resuspended in PBS or FACS buffer.
For in vivo xenograft assays, female Rag2-/-γc-/mice were injected subcutaneously with the indicated
number of viable cells, after cell dissociation, washing,
and suspension in PBS. Tumor growth was monitored
twice a week and tumor diameters were measured using
an electronic calliper to determine the tumor size by
multiplying perpendicular diameters.

Lentiviral production
For the production of the lentiviral particles, the
cell line HEK293T was transfected, using CaCl2, with the
packaging plasmid pCMV-dR8.2, the envelope plasmid
pCMV-VSVG and the lentiviral construct containing the
shRNA or the transgene. Cell culture medium was changed
16 hours after the transfection and virus supernatants
were collected 24 and 48 hours after the media change.
Immediately after supernatant collection, the viral
particles were concentrated by ultracentrifugation. The
lentiviral pellets were then resuspended in ice-cold PBS
and the virus was titrated by FACS using HEK293T
cells. To calculate the biological titer of the virus, the
following formula was used: TU/μl = (P × N/Vx100)
× 1/DF, where TU stands for Transducing Units, P = %
Zsgreen+ or mCherry+ cells, N = number of cells at time
of transduction = 10^5, V= volume of dilution added to
each well = 20 μl, and DF = dilution factor = 1 (undiluted),
10^−1 (diluted 1/10), 10^−2 (diluted 1/100), and so on.

Quantitative RT-PCR
The relative abundance of p75NTR mRNA was
analysed by quantitative real-time reverse transcriptionPolymerase Chain Reaction (RT-PCR) of SCC-4, UMSCC-6, UPCI:SCC-103 and PCI-13 cells. Briefly, cell
cultures were rinsed with ice-cold PBS and then the cells
were lysed and scraped off using Trizol (Invitrogen).
Afterwards, chloroform (Sigma) was added and the
mixture was centrifuged. RNA was recovered from
the aqueous phase by precipitation with 2-propanol.
The extracted RNA was treated with Turbo DNase to
remove genomic DNA prior to reverse transcription with
Superscript III Reverse Transcriptase (Invitrogen). Finally,
real-time RT-PCR was performed using a specific Taqman
Assay for the human p75NTR sequence. Human HPRT1
was amplified as control. The amount of p75NTR mRNA
was expressed as arbitrary units defined as the n-fold
difference relative to the control gene HPRT1 (2ΔCt ×100,
where ΔCt represents the difference in threshold cycle
between the control and target genes).

Lentiviral transduction
For the lentiviral transduction of the cell lines, cells
were harvested, washed, resuspended in fresh medium
and plated at the appropriate concentration (1x106 cells
per 10 cm plates). Then, the lentiviral particles were added
to the cell cultures at a multiplicity of infection (MOI) of
1 transducing Unit per cell. Polybrene (8ug/ml) was also
added to enhance the lentiviral transduction efficiency.
48 hours after viral infection, medium was changed. In
the case of the cells transduced with the pLKO.1 puro
vectors, the cell cultures were treated with the selection
agent puromycin for 3 days after media change.

Lentiviral Plasmids
The lenti-vectors pLKO.1 puro and pLKO.1
mCherry were kind gifts from Dr. Alejandro SweetCordero (Stanford). The following shRNAs against
p75NTR were AgeI/EcoRI inserted into the pLKO.1 vectors:
www.impactjournals.com/oncotarget
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XTT and MTT Assays

Flow Cytometry Analysis

The XTT and MTT assays were carried out
following the manufacturer’s instructions (Roche Applied
Science, Germany). Briefly, FACS-sorted cells were
seeded into 96-well plates at a concentration of 500 to
1500 cells per well in 100ul of culture medium. The XTT
labelling mixture was added to the wells at different time
points and incubated for 20 hours at 37 C before reading
the plate in an ELISA reader at a wavelength of 450-500
nm. For the MTT assays, MTT labelling reagent was
added to the wells first. Then the plates were incubated for
4 hours at 37 C and finally the solubilisation buffer was
added to the wells and incubated at 37C for another 16
hours before evaluating the plate in an ELISA reader at a
wavelength of 550-600nm.

Cells were harvested from culture flasks or isolated
from mouse xenografts after tumor dissociation, as
described above. Single-cell suspensions were then pretreated with IgG from mouse serum to block non-specific
staining and incubated with the appropriate antibodies.
DAPI was used to allow exclusion of non-viable cells;
in the case of mouse xenografts, anti-mouse H-2Kd FITC
antibody (SF1-1.1) was added to exclude mouse cells
from the analysis. Then, CD44 and CD271 expression
was assessed after exclusion of lineage+ cells (CD45+ cells,
CD31+ cells, and TE-7+ fibroblasts).
To determine the percentage of cells within the
PCI-13 cell line that were actively undergoing apoptosis
after p75NTR knock down, the FITC Annexin V Kit from
BD Pharmingen was used following the manufacturer’s
instructions. Briefly, cells were washed twice in icecold PBS and resuspended in 1x binding buffer at a
concentration of 1x106 cells/ml. The cells were then
incubated in the presence of Annexin V and PI for 15
minutes at room temperature in the dark. After the
15-minute incubation, 400ul of 1x binding buffer was
added to each tube and the samples were analysed within
1 hour.

CD271 Rescue Experiment
To validate the selectivity of the shRNAs 3a and
5a for p75NTR gene, a rescue experiment was performed
employing an expression construct containing a p75NTR
cDNA that was resistant to the shRNAs. Briefly, PCI-13
cells were transduced first with the lenti-vector pHIVZsgreen containing the cDNA of human p75NTR that lacked
the 3’UTR region. 5 days after transduction, Zsgreen+ cells
were sorted out by FACS. Afterwards, these cells were cotransduced with the shRNAs 3a or 5a that were designed
to the 3’UTR region of p75NTR mRNA. 5 days later, cells
were FACS-sorted again based on the expression of
Zsgeen and mCherry. The double-sorted cells were then
plated into 96-well plates (500-1500 cells per well) to
carry out a XTT or MTT assay.

Cell Cycle Analysis
For the cell cycle analysis, the oral squamous cancer
cell line PCI-13 was transduced with lentiviral vectors
carrying the specific shRNAs against p75NTR shRNA 3a
or shRNA 5a or with the empty lenti-vector pLKO.1.
puro. Two days after the viral transduction, the selective
agent puromycin was added to get rid of the untransduced
cells. After 3 days in the presence of the selection drug,
the medium was changed and BrdU was added to the cell
cultures for 4 hours. After the 4-hour incubation, the cells
were harvested and washed with PBS twice to remove the
non-incorporated BrdU. Then the BrdU labelled cells were
fixed with 70% ethanol and kept at -20 degrees for at least
2 hours. The day of the experiment, the cells were thawed
and rehydrated in PBS for 15 minutes. DNA was denatured
by adding drop-wise a solution containing 2M HCl and
0.5% of Triton-X100. After a 20-minute incubation, the
acid solution was neutralized using 0.1M sodium borate
at pH 8.5. Finally, the samples were incubated in the
presence of anti-BrdU FITC antibody (BD Pharmingen)
for 30 minutes, washed and added a solution containing
PI and RNase A just before they were analysed by FACS.

In vivo Tumor Growth Competition Assay
For the competition assay, the cell line PCI-13 was
transduced with the lentiviral construct pHIV-Zsgreen
(green) or with the lenti-vector pLKO.1 mCherry (red)
containing or not the specific shRNAs against p75NTR 3a
and 5a. Two days later, the culture medium was changed
and five days after the viral transduction, the cells were
harvested and washed twice with ice-cold PBS. The singlecell suspensions were then FACS-sorted based on the
expression of the reporter molecules Zsgreen (green) and
mCherry (red). The double-sorted red and green cells were
mixed in similar amounts and injected subcutaneously into
immunocompromised Rag2-/-γc-/- mice. The tumors that
arose in those mice were harvested when they reached 1.5
cm in diameter and were dissociated using collagenasehyaluronidase from StemCell Technologies following
the manufacturer’s instructions. Finally, the dissociatedtumors were analysed by flow cytometry.
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Targeting CD271 in vitro and in vivo
PCI-13 cells were incubated with either azide-free
monoclonal antibody specific for CD271 (clone NGFR5,
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